![]() |
市場調查報告書
商品編碼
1355822
獸醫自體免疫疾病治療市場 - 按治療(皮質類固醇、硫唑嘌呤)、疾病(甲狀腺功能減退症、天皰瘡)、動物類型(伴侶、牲畜)、配銷通路(醫院、診所)、全球預測( 2023 - 2032)Veterinary Autoimmune Disease Therapeutics Market - By Therapy, Disease, Animal Type, Distribution Channel, Global Forecast (2023 - 2032) |
2023年至2032年,全球獸醫自體免疫疾病治療市場的複合年成長率將超過5.3%。包括狗和貓在內的動物自體免疫疾病發生率的上升推動了對有效治療的需求。寵物飼養量的增加以及人類與寵物之間聯繫的加深有助於人們願意投資先進的治療方法。
例如,根據《富比士》2023 年6 月的一份報告,美國寵物擁有率達到66%,覆蓋8,690 萬個家庭,比1988 年的56% 有所增加。這些統計數據證明了寵物在人們生活中的持久重要性。對許多人來說,寵物提供陪伴和情感支持,85% 的狗主人和 76% 的貓主人認為他們毛茸茸的朋友是不可或缺的家庭成員。獸醫學和診斷學的進步正在擴大治療選擇。此外,人們對動物自體免疫疾病的認知不斷提高,促進了獸醫自體免疫疾病治療市場的成長。
整個獸醫自體免疫疾病治療市場根據治療、疾病和地區進行分類。
硫唑嘌呤細分市場將在 2023 年至 2032 年間經歷重大發展。硫唑嘌呤是一種重要的免疫抑制藥物,用於治療動物自體免疫疾病。其在控制過度免疫反應和減輕發炎和器官損傷等症狀方面的功效使其成為獸醫自體免疫疾病治療中廣受歡迎的治療選擇,極大地滿足了獸醫自身免疫疾病治療的市場需求。
從 2023 年到 2032 年,天皰瘡疾病領域的複合年成長率將值得稱讚。天皰瘡是一種影響寵物的自體免疫疾病,會導致皮膚和黏膜病變疼痛。需要獸醫自體免疫疾病治療藥物,包括皮質類固醇和免疫抑制劑等藥物來控制和緩解天皰瘡症狀,改善受影響動物的生活品質並推動獸醫自體免疫疾病治療市場收入。
2023年至2032年,歐洲獸醫自體免疫疾病治療市場將呈現可觀的複合年成長率。該地區對寵物根深蒂固的喜愛、嚴格的動物福利標準和先進的獸醫護理基礎設施推動了對自身免疫性疾病治療的需求。各國加強遏制虐待動物,支持了該地區市場的成長。例如,根據2022年6月消息,法國立法者於2021年11月通過了《對待動物法》修正案。根據該修正案,從2024年開始,寵物商店將被禁止展示和銷售狗和貓。
此外,公眾將不再被允許進行涉及貓狗的線上交易。該法規旨在解決不斷升級的遺棄寵物問題,該問題在 COVID-19 大流行期間有所增加。隨著人們對寵物健康和自體免疫疾病的認知不斷提高,歐洲仍然是獸醫自體免疫疾病治療的重要市場,支持整個非洲大陸深受喜愛的伴侶動物的福祉。
Global Veterinary Autoimmune Disease Therapeutics Market will witness over 5.3% CAGR between 2023 and 2032. The rising incidence of autoimmune diseases in animals, including dogs and cats, propels the demand for effective treatments. Increasing pet ownership and the deepening bond between humans and their pets contribute to a willingness to invest in advanced treatments.
For instance, according to a Forbes report from June 2023, pet ownership in the United States reached 66%, encompassing 86.9 million households-an increase from 56% recorded in 1988. These statistics prove the enduring significance of pets in people's lives. For many, pets provide companionship and emotional support, with 85% of dog owners and 76% of cat owners considering their furry friends as integral family members. Advancements in veterinary medicine and diagnostics are expanding treatment options. Additionally, the growing awareness of autoimmune conditions in animals fosters veterinary autoimmune disease therapeutics market growth.
The overall Veterinary Autoimmune Disease Therapeutics Market is classified based on therapy, disease, and region.
The azathioprine segment will undergo significant development from 2023 to 2032. Azathioprine is a crucial immunosuppressive drug used to manage autoimmune disorders in animals. Its efficacy in controlling excessive immune responses and alleviating symptoms like inflammation and organ damage makes it a sought-after treatment option in veterinary autoimmune disease therapeutics, contributing significantly to veterinary autoimmune disease therapeutics market demand.
The pemphigus disease segment will register a commendable CAGR from 2023 to 2032. Pemphigus is an autoimmune condition that affects pets, leading to painful skin and mucous membrane lesions. Veterinary autoimmune disease therapeutics, including medications like corticosteroids and immunosuppressants, are in demand to manage and alleviate the symptoms of pemphigus, improving the quality of life for affected animals and driving veterinary autoimmune disease therapeutics market revenue.
Europe veterinary autoimmune disease therapeutics market will showcase an appreciable CAGR from 2023 to 2032. The region's deep-rooted affection for pets, stringent animal welfare standards, and advanced veterinary care infrastructure drive the need for autoimmune disease therapeutics. Increasing efforts from countries to curb the mistreatment of animals support market growth in the region. For instance, according to news from June 2022, French lawmakers passed an amendment to the Act on the Treatment of Animals in November 2021. According to this amendment, pet stores will be prohibited from exhibiting and selling dogs and cats starting in 2024.
In addition, the public will no longer be permitted to conduct online transactions involving dogs and cats. The regulation intends to combat the escalating issue of pet abandonment, which witnessed an increase during the COVID-19 pandemic. With increasing awareness of pet health and autoimmune conditions, Europe remains a significant market for veterinary autoimmune disease treatments, supporting the well-being of beloved companion animals across the continent.